Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism
- Registration Number
- NCT00633893
- Lead Sponsor
- Bristol-Myers Squibb
- Brief Summary
The purpose is to evaluate the effects of an investigational blood thinner, apixaban, in preventing venous thromboembolic (VTE) recurrence or death in patients who have completed their intended treatment for deep vein thrombosis (DVT) or pulmonary embolism (PE)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 2711
- Men and women ≥ 18 years of age;
- Clinical diagnosis of Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE);
- Anticoagulant treatment completed
- No recurrence of Venous Thromboembolism (VTE)
- Subjects with indications for long-term treatment with a vitamin K antagonist
- Active bleeding or high risk for serious bleeding
- Short life expectancy
- Uncontrolled high blood pressure
- Impaired kidney or liver function
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 1 Apixaban 2.5 mg 3 Placebo 0 mg 2 Apixaban 5.0 mg
- Primary Outcome Measures
Name Time Method Adjudicated Composite of Symptomatic, Recurrent Venous Thromboembolism (VTE) or All-Cause Death During the Intended Treatment Period - Randomized Population With Imputation Day 1 up to 12 Months VTE included: nonfatal deep vein thrombosis (DVT) or nonfatal pulmonary embolism (PE). All index events, DVT and/or PE were adjudicated/confirmed by a central independent adjudication committee blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of events; N=number of participants). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Composite endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. For missing endpoint data, participants were imputed as having had a primary efficacy outcome event.
Adjudicated Composite of Symptomatic, Recurrent Venous Thromboembolism (VTE) or All-Cause Death During the Intended Treatment Period - Randomized Population Without Imputation Day 1 up to 12 months VTE included: nonfatal DVT or nonfatal PE. Event rate (proportion of participants with event) calculated as n/N (n=number of events; N=number of participants). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Composite endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. No imputation was done for these endpoints; participants who had an event during the intended treatment period were counted. Confidence interval (CI) for single event rate was calculated based on the Wald asymptotic confidence limits.
- Secondary Outcome Measures
Name Time Method Adjudicated Composite of Recurrent, Symptomatic Venous Thromboembolism (VTE) or VTE-related Death During the Intended Treatment Period - Randomized Population With Imputation Day 1 up to 12 Months VTE includes nonfatal DVT or nonfatal PE. All index events, DVT and/or PE were adjudicated/confirmed by a central independent adjudication committee blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of events; N=number of participants). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Composite endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. For missing endpoint data, participants were imputed as having had a primary efficacy outcome event.
Adjudicated Composite of Major/Clinically Relevant Non-major Bleeding During the Treatment Period - Treated Participants Day 1 up to 12 Months Major bleeding and clinically relevant non-major bleeding were adjudicated/confirmed by a central independent adjudication committee blinded to treatment. Major bleeding was defined as acute clinically overt bleeding: associated with a fall in hemoglobin of 2 g/dL or more, or leading to a transfusion of 2 or more units of packed red blood cells or 1000 mL or more of whole blood, or in a critical site: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal, or another critical organ or is fatal. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). CI for single event rate was calculated based on the Wald asymptotic confidence limits. Treated population includes randomized participants who received at least one dose of study drug.
Adjudicated Composite of Recurrent, Symptomatic Venous Thromboembolism (VTE) or Cardio Vascular (CV) -Related Death During the Intended Treatment Period - Randomized Population With Imputation Day 1 up to 12 Months VTE includes nonfatal DVT or nonfatal PE. All index events, DVT and/or PE were adjudicated/confirmed by a central independent adjudication committee blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Composite endpoint included events that occurred any time from randomization until end of the intended treatment period, regardless of whether the participants were receiving drug treatment. Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. If there were missing endpoint data, participants were imputed as having had an efficacy outcome event.
Adjudicated Cardiovascular (CV)-Related Death During the Intended Treatment Period - Randomized Population With Imputation Day 1 up to 12 Months CV-related death was defined as myocardial infarction, stroke, or other specified cardiovascular event and were adjudicated/confirmed by a central independent adjudication committee blinded to treatment. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. Participants with missing endpoint information were classified as having had the efficacy event (imputation). CI for single event rate was calculated based on the Wald asymptotic confidence limits.
Adjudicated All-Cause Death During the Intended Treatment Period - Randomized Population With Imputation Day 1 up to 12 Months DVT and/or PE were adjudicated/confirmed by a central independent adjudication committee blinded to treatment: DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. New/recurrent VTE, death, venous/arterial thromboembolic events, bleeding, thrombocytopenia, acute myocardial infarction and stroke were also adjudicated. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Participants with missing endpoint information were classified as having had the efficacy event (imputation). CI for single event rate was calculated based on the Wald asymptotic confidence limits.
Number of Participants With an Adjudicated Symptomatic Nonfatal Venous Thromboembolism (VTE) Recurrence or Death (All Cause) During the Intended Treatment Period - Randomized Participants Without Imputation Day 1 up to 12 Months All index events, DVT and/or PE were adjudicated/confirmed by a central independent adjudication committee blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. First event category was the first primary event for each participant and each participant was counted once. CV-related death was presented excluding VTE-related death. In participants with event category, each participant was counted once in each event category but could have been counted in multiple categories. No imputation was done for these endpoints; participants who had an event during the intended treatment period were counted.
Adjudicated Total Bleeding During the Treatment Period - Treated Participants Day 1 up to 12 months All bleeding events were adjudicated/confirmed by a central independent adjudication committee blinded to treatment. Total bleeding was defined as any major, clinically relevant non-major, or minor bleeding. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). CI for single event rate was calculated based on the Wald asymptotic confidence limits. Treated population includes randomized participants who received at least one dose of study drug.
Adjudicated Composite of Recurrent, Symptomatic Venous Thromboembolism (VTE) or Venous Thromboembolism-related Death During the Intended Treatment Period - Randomized Population Without Imputation Day 1 up to 12 Months VTE related death defined as PE (based on objective diagnostic testing, autopsy), unexplained death (and VTE cannot be ruled out), sudden death (and VTE cannot be ruled out). DVT and/or PE were adjudicated/confirmed by a central independent adjudication committee blinded to treatment: DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. New/recurrent VTE and death, were also adjudicated. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. No imputation was done for these endpoints.
Adjudicated Nonfatal Deep Vein Thrombosis (DVT) During the Intended Treatment Period - Randomized Population With Imputation Day 1 up to 12 Months DVT was adjudicated/confirmed by a central independent adjudication committee blinded to treatment and assessed by compression ultrasound and/or venography. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. Participants with missing endpoint information were classified as having had the efficacy event (imputation). Confidence interval (CI) for single event rate was calculated based on the Wald asymptotic confidence limits.
Adjudicated Nonfatal Pulmonary Embolism (PE) During the Intended Treatment Period - Randomized Population With Imputation Day 1 up to 12 Months PE was adjudicated/confirmed by a central independent adjudication committee blinded to treatment and was assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. Participants with missing endpoint information were classified as having had the efficacy event (imputation). CI for single event rate was calculated based on the Wald asymptotic confidence limits.
Adjudicated Venous Thromboembolism (VTE) - Related Death During the Intended Treatment Period - Randomized Population With Imputation Day 1 up to 12 Months VTE-related death defined as: PE (based on objective diagnostic testing, autopsy), unexplained death (and VTE cannot be ruled out), sudden death (and VTE cannot be ruled out). DVT and/or PE were adjudicated/confirmed by a central independent adjudication committee blinded to treatment: DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. New/recurrent VTE, death, venous/arterial thromboembolic events, bleeding, thrombocytopenia, acute myocardial infarction and stroke were also adjudicated. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Participants with missing endpoint information were classified as having had the efficacy event (imputation).
Adjudicated Major Bleeding During the Treatment Period - Treated Population Day 1 up to 12 Months Major bleeding was adjudicated/confirmed by a central independent adjudication committee blinded to treatment and was defined as acute clinically overt bleeding: associated with a fall in hemoglobin of 2 grams per deciliter (g/dL) or more, or leading to a transfusion of 2 or more units of packed red blood cells or 1000 milliliters (mL) or more of whole blood, or in a critical site: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal, or another critical organ; or is fatal. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Confidence interval (CI) for event rate was calculated based on the Wald asymptotic confidence limits. Treated population includes randomized participants who received at least one dose of study drug.
Adjudicated Composite of Recurrent, Symptomatic Venous Thromboembolism (VTE) or Cardio Vascular (CV) - Related Death During the Intended Treatment Period - Randomized Population Without Imputation Day 1 up to 12 Months CV-related death was defined as myocardial infarction, stroke, or other specified cardiovascular event. Index events of DVT and/or PE, along with myocardial infarction and stroke were adjudicated/confirmed by a central independent adjudication committee blinded to treatment: DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Composite endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. No imputation was done for these endpoints; participants who had an event during the intended treatment period were counted.
Adjudicated Clinically Relevant Minor Bleeding During the Treatment Period - Treated Participants Day 1 up to 12 months All bleeding events were reviewed by the central independent adjudication committee blinded to treatment and classified as major bleeding, clinically relevant non-major bleeding, minor bleeding or no bleeding. If event was not major or clinically relevant non-major, it was judged to be minor. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Confidence interval (CI) for single event rate was calculated based on the Wald asymptotic confidence limits. Treated population includes randomized participants who received at least one dose of study drug.
Adjudicated Nonfatal Pulmonary Embolism (PE) During the Intended Treatment Period - Randomized Population Without Imputation Day 1 up to 12 Months PE was adjudicated/confirmed by a central independent adjudication committee blinded to treatment: PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. No imputation was done for this endpoint; participants who had an event during the intended treatment period were counted.
Adjudicated Clinically Relevant Non-major Bleeding During the Treatment Period - Treated Participants Day 1 up to 12 months Non-major clinically relevant bleeding was adjudicated/confirmed by a central independent adjudication committee blinded to treatment and defined as: acute clinically overt bleeding compromising hemodynamics; leading to hospitalization; traumatic subcutaneous hematoma; intramuscular hematoma; epistaxis that lasted for more than 5 minutes, was repetitive or led to an intervention; spontaneous gingival bleeding (or lasting more than 5 minutes); spontaneous hematuria (macroscopic or lasted more than 24 hours after instrumentation of the urogenital tract); macroscopic gastrointestinal hemorrhage (including at least 1 episode of melena or hematemesis (if clinically apparent with positive results on a fecal occult-blood test); rectal blood loss. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). CI for single event rate was calculated based on the Wald asymptotic confidence limits.
Adjudicated Nonfatal Deep Vein Thrombosis (DVT) During the Intended Treatment Period - Randomized Population Without Imputation Day 1 up to 12 Months DVT was adjudicated/confirmed by a central independent adjudication committee blinded to treatment: DVT assessed by compression ultrasound and/or venography. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. No imputation was done for this endpoint; participants who had an event during the intended treatment period were counted.
Adjudicated Venous Thromboembolism (VTE)- Related Death During the Intended Treatment Period - Randomized Population Without Imputation Day 1 up to 12 Months VTE related death defined as PE (based on objective diagnostic testing, autopsy), unexplained death (and VTE cannot be ruled out), sudden death (and VTE cannot be ruled out). DVT and/or PE were adjudicated/confirmed by a central independent adjudication committee blinded to treatment: DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. New/recurrent VTE, and death, were also adjudicated. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. No imputation was done for this endpoint.
Adjudicated Cardio Vascular (CV)-Related Death During the Intended Treatment Period - Randomized Population Without Imputation Day 1 up to 12 Months CV-related death was defined as myocardial infarction, stroke, or other specified cardiovascular event and these were adjudicated/confirmed by a central independent adjudication committee blinded to treatment. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. No imputation was done for this endpoint; participants who had an event during the intended treatment period were counted.
Adjudicated All-Cause Death During the Intended Treatment Period - Randomized Population Without Imputation Day 1 up to 12 Months DVT and/or PE were adjudicated/confirmed by a central independent adjudication committee blinded to treatment: DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. New/recurrent VTE, death, venous/arterial thromboembolic events, bleeding, thrombocytopenia, acute myocardial infarction and stroke were also adjudicated. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. No imputation was done for this endpoint; participants who had an event during the intended treatment period were counted.
Trial Locations
- Locations (87)
Mercury Street Medical Group, Pllc
🇺🇸Butte, Montana, United States
Piedmont Healthcare/Research
🇺🇸Statesville, North Carolina, United States
William Beaumont Hospital
🇺🇸Royal Oak, Michigan, United States
Akron General Medical Center
🇺🇸Akron, Ohio, United States
Robert J. Bloomberg, Md, Pc
🇺🇸Tempe, Arizona, United States
Richard A. Mclean M.D., P.A.
🇺🇸Plantation, Florida, United States
Infectious Disease Of Indiana Psc
🇺🇸Carmel, Indiana, United States
Ohio State University Medical Center
🇺🇸Columbus, Ohio, United States
Remington Davis Inc.
🇺🇸Columbus, Ohio, United States
University Of Virginia Health System
🇺🇸Charlottesville, Virginia, United States
Ankur Doshi, Md
🇺🇸Houston, Texas, United States
South Miami Heart Center
🇺🇸Miami, Florida, United States
Thomas L. Ortel, Md, Phd
🇺🇸Durham, North Carolina, United States
New West Physicians
🇺🇸Golden, Colorado, United States
Saltzer Medical Group
🇺🇸Nampa, Idaho, United States
New York Medical College
🇺🇸Valhalla, New York, United States
Henry Ford Hospital
🇺🇸Detroit, Michigan, United States
Alabama Clinical Therapeutics, Llc
🇺🇸Birmingham, Alabama, United States
Cardiovascular Consultants, Ltd.
🇺🇸Phoenix, Arizona, United States
Creighton University Medical Center
🇺🇸Omaha, Nebraska, United States
Cor Clinical Research, Llc
🇺🇸Oklahoma City, Oklahoma, United States
University Of Utah Hospital
🇺🇸Salt Lake City, Utah, United States
Tampa Clinical Research
🇺🇸Tampa, Florida, United States
Jobst Vascular Center At The Toledo Hospital
🇺🇸Toledo, Ohio, United States
Scripps Clinic/Scripps Health And Green Hospital
🇺🇸La Jolla, California, United States
Healthcare Partners Medical Group
🇺🇸Los Angeles, California, United States
Beaver Medical Group
🇺🇸Banning, California, United States
Mission Internal Medical Group
🇺🇸Mission Viejo, California, United States
Fort Smith Lung Center
🇺🇸Fort Smith, Arkansas, United States
Indus Clinical Research Institute, Inc.
🇺🇸Pomona, California, United States
Desert Med Grp Inc, Dba Desert Oasis Healthcare Med Group
🇺🇸Palm Springs, California, United States
Stanford University Medical Center
🇺🇸Stanford, California, United States
Kaiser Permanente Medical Center
🇺🇸San Francisco, California, United States
Harbor Ucla Medical Center
🇺🇸Torrance, California, United States
Progressive Clinical Research
🇺🇸Vista, California, United States
Alfieri Cardiology
🇺🇸Newark, Delaware, United States
Healthworx
🇺🇸Hollywood, Florida, United States
St. Francis Sleep Allergy & Lung Institute
🇺🇸Clearwater, Florida, United States
Berma Research Group
🇺🇸Fort Lauderdale, Florida, United States
Research Alliance, Inc.
🇺🇸Clearwater, Florida, United States
Hematology Oncology Associates
🇺🇸Loxahatchee, Florida, United States
Bay Pines Va Healthcare Systems
🇺🇸Bay Pines, Florida, United States
Physicians Regional Medical Group
🇺🇸Naples, Florida, United States
Primary Care Of The Treasure Coast, Inc.
🇺🇸Vero Beach, Florida, United States
Cleveland Clinic Florida
🇺🇸Weston, Florida, United States
Vascular Surgical Associates, Pc
🇺🇸Austell, Georgia, United States
Gwinnett Biomedical Research
🇺🇸Lawrenceville, Georgia, United States
Boise Orthopedic Clinic
🇺🇸Boise, Idaho, United States
Atlanta Institute For Medical Research, Inc
🇺🇸Decatur, Georgia, United States
Office Of:Eugene C. Fletcher, Md
🇺🇸New Albany, Indiana, United States
Heartland Vascular Medicine And Surgery
🇺🇸Windsor Heights, Iowa, United States
Kentucky Lung Clinic
🇺🇸Hazard, Kentucky, United States
Owensboro Heart & Vascular
🇺🇸Owensboro, Kentucky, United States
Cape Cod Research Institute
🇺🇸Hyannis, Massachusetts, United States
Pen Bay Medical Center
🇺🇸Rockport, Maine, United States
Anne Arundel Health System Research Institute, Inc.
🇺🇸Annapolis, Maryland, United States
Great Falls Clinic, Llp
🇺🇸Great Falls, Montana, United States
Internal Medical Associates Of Grand Island, P.C
🇺🇸Grand Island, Nebraska, United States
Kaleida Health System
🇺🇸Buffalo, New York, United States
Goshen Medical Associates
🇺🇸Goshen, New York, United States
Sjh Cardiology Associates
🇺🇸Liverpool, New York, United States
Richmond University Medical Center
🇺🇸Staten Island, New York, United States
Rex Healthcare
🇺🇸Raleigh, North Carolina, United States
Whiteville Medical Associates, P.A.
🇺🇸Whiteville, North Carolina, United States
Valley Internal Medicine
🇺🇸Fayetteville, North Carolina, United States
Wilmington Medical Research
🇺🇸Wilmington, North Carolina, United States
Community Health Care, Inc.
🇺🇸Canal Fulton, Ohio, United States
Valley Medical Research
🇺🇸Centerville, Ohio, United States
Greenville Hospital System
🇺🇸Greenville, South Carolina, United States
Pma Medical Specialists
🇺🇸Phoenixville, Pennsylvania, United States
Three Rivers Medical Associates, Pa
🇺🇸Irmo, South Carolina, United States
Clinical Research Authority, Llc
🇺🇸Murrells Inlet, South Carolina, United States
Palmetto Clinical Research
🇺🇸Summerville, South Carolina, United States
Corsicana Medical Research
🇺🇸Corsicana, Texas, United States
Holston Medical Group
🇺🇸Kingsport, Tennessee, United States
Amarillo Heart Clinical Research Institute Inc.
🇺🇸Amarillo, Texas, United States
Tanner Clinic
🇺🇸Layton, Utah, United States
Northwest Heart Center
🇺🇸Tomball, Texas, United States
Lake Washington Vascular, Pllc
🇺🇸Bellevue, Washington, United States
Sentara York Clinical Research
🇺🇸Norfolk, Virginia, United States
Local Institution
🇬🇧Dudley, West Midlands, United Kingdom
Franciscan Research Center
🇺🇸Tacoma, Washington, United States
Medical Assoicates Inc.
🇺🇸Menomonee Falls, Wisconsin, United States
Rocky Mountain Internal Medicine
🇺🇸Aurora, Colorado, United States
Veterans Affairs Medical Center
🇺🇸Kansas City, Missouri, United States
Charleston Hematology Oncology Associates, Pa
🇺🇸Charleston, South Carolina, United States
Rhode Island Hospital
🇺🇸Providence, Rhode Island, United States